Healthcare

•Ramsay is concentrating its strategy on Australian hospitals and UK healthcare operations as it progresses the proposed separation of Ramsay Santé.

• Commercial execution depends on distribution, prescriber awareness and patient adoption.

• Practitioner and retail channels give the company several routes to customers.

EBR Systems (ASX:EBR) has reached an important manufacturing milestone as it continues the US commercial rollout of its WiSE System.

Prescient Therapeutics (ASX:PTX) has reached an important operational milestone in the Phase 2a study of PTX-100 for relapsed or refractory cutaneous T-cell lymphoma, with 20 evaluable patients now enrolled across the two dosing arms.

CONNEQT Health (ASX:CQT) finished FY2026 with a materially stronger revenue profile, supported by consumer sales and research-related income. However, the company’s financial position remains a central part of theInvestmentcase, with a relatively modest cash balance, ongoing operating outflows and negativeShareholderequity.

Neurizon Therapeutics (ASX:NUZ) has added another significant component to the clinical development program for NUZ-001, with the US National Institutes of Health funding an Expanded Access Program designed to provide the investigational therapy to a broader population of people living with amyotrophic lateral sclerosis.